Sustainability in Biopharma: A Review of Environmental Considerations in Manufacturing Processes

Abstract

Waste disposal, CO2 emissions, plastic use, air pollution, and energy and water consumption—including that associated with the transportation and refrigeration of pharmaceuticals—all contribute to the substantial environmental effect of pharmaceutical enterprises. According to figures from 2019, pharmaceutical companies' CO2 emissions were 13% more than those of the automobile sector. To adopt a more sustainable approach, pharmaceutical companies should prioritize investments in eco-friendly production and supply methods, establish standard criteria, implement rewards programs, and provide staff training. Paracelsus famously noted in the sixteenth century that "the dose makes the poison, Because only a small portion of the population receives a given dosage, environmental concentrations of medicines expelled by people are usually modest. Recent research, however, has shown that direct emissions from the production of pharmaceuticals can lead to far greater environmental discharges, frequently exceeding dangerous threshold values. The dangers involved are not affected by consumption patterns since manufacturing is confined. Furthermore, human metabolism does not lower the concentrations of these medications since they are not consumed. As a result, manufacturing-related environmental hazards cover a wider variety of medications than excretion-related ones. Manufacturing pollution is less common, yet it may nevertheless have an impact on the entire world by encouraging the growth of microbes that are resistant to drugs.